• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非小细胞肺癌患者来源类肿瘤体及其微环境的血管生成

Vascularization of Patient-Derived Tumoroid from Non-Small-Cell Lung Cancer and Its Microenvironment.

作者信息

Seitlinger Joseph, Nounsi Anasse, Idoux-Gillet Ysia, Santos Pujol Eloy, Lê Hélène, Grandgirard Erwan, Olland Anne, Lindner Véronique, Zaupa Cécile, Balloul Jean-Marc, Quemeneur Eric, Massard Gilbert, Falcoz Pierre-Emmanuel, Hua Guoqiang, Benkirane-Jessel Nadia

机构信息

INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France.

1 Place de l'Hôpital, University Hospital Strasbourg (HUS), 67000 Strasbourg, France.

出版信息

Biomedicines. 2022 May 10;10(5):1103. doi: 10.3390/biomedicines10051103.

DOI:10.3390/biomedicines10051103
PMID:35625840
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9138465/
Abstract

Patient-derived tumoroid (PDT) has been developed and used for anti-drug screening in the last decade. As compared to other existing drug screening models, a PDT-based in vitro 3D cell culture model could preserve the histological and mutational characteristics of their corresponding tumors and mimic the tumor microenvironment. However, few studies have been carried out to improve the microvascular network connecting the PDT and its surrounding microenvironment, knowing that poor tumor-selective drug transport and delivery is one of the major reasons for both the failure of anti-cancer drug screens and resistance in clinical treatment. In this study, we formed vascularized PDTs in six days using multiple cell types which maintain the histopathological features of the original cancer tissue. Furthermore, our results demonstrated a vascular network connecting PDT and its surrounding microenvironment. This fast and promising PDT model opens new perspectives for personalized medicine: this model could easily be used to test all therapeutic treatments and could be connected with a microfluidic device for more accurate drug screening.

摘要

患者来源的类肿瘤(PDT)在过去十年中得到了发展并用于抗药物筛选。与其他现有的药物筛选模型相比,基于PDT的体外3D细胞培养模型可以保留其相应肿瘤的组织学和突变特征,并模拟肿瘤微环境。然而,尽管已知肿瘤选择性药物转运和递送不佳是抗癌药物筛选失败和临床治疗耐药的主要原因之一,但很少有研究致力于改善连接PDT及其周围微环境的微血管网络。在本研究中,我们使用多种细胞类型在六天内形成了血管化的PDT,这些细胞类型保持了原始癌组织的组织病理学特征。此外,我们的结果证明了连接PDT及其周围微环境的血管网络。这种快速且有前景的PDT模型为个性化医学开辟了新的前景:该模型可轻松用于测试所有治疗方法,并可与微流控设备连接以进行更精确的药物筛选。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c1a/9138465/f85ede22cca5/biomedicines-10-01103-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c1a/9138465/38ec0943d75e/biomedicines-10-01103-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c1a/9138465/9fab79a5f46a/biomedicines-10-01103-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c1a/9138465/491bccc7544c/biomedicines-10-01103-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c1a/9138465/c7239d5a435b/biomedicines-10-01103-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c1a/9138465/f85ede22cca5/biomedicines-10-01103-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c1a/9138465/38ec0943d75e/biomedicines-10-01103-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c1a/9138465/9fab79a5f46a/biomedicines-10-01103-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c1a/9138465/491bccc7544c/biomedicines-10-01103-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c1a/9138465/c7239d5a435b/biomedicines-10-01103-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c1a/9138465/f85ede22cca5/biomedicines-10-01103-g005.jpg

相似文献

1
Vascularization of Patient-Derived Tumoroid from Non-Small-Cell Lung Cancer and Its Microenvironment.非小细胞肺癌患者来源类肿瘤体及其微环境的血管生成
Biomedicines. 2022 May 10;10(5):1103. doi: 10.3390/biomedicines10051103.
2
vascularized immunocompetent patient-derived model to test cancer therapies.用于测试癌症治疗方法的血管化免疫活性患者来源模型。
iScience. 2023 Sep 29;26(10):108094. doi: 10.1016/j.isci.2023.108094. eCollection 2023 Oct 20.
3
Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures.基于肿瘤类器官和组织切片培养分子特征,应用三维肿瘤类器官系统来定义免疫和细胞毒性治疗反应。
Oncotarget. 2017 Aug 5;8(40):66747-66757. doi: 10.18632/oncotarget.19965. eCollection 2017 Sep 15.
4
Patient-Derived Tumoroid for the Prediction of Radiotherapy and Chemotherapy Responses in Non-Small-Cell Lung Cancer.用于预测非小细胞肺癌放疗和化疗反应的患者来源类肿瘤体
Biomedicines. 2023 Jun 26;11(7):1824. doi: 10.3390/biomedicines11071824.
5
The design and characterization of a gravitational microfluidic platform for drug sensitivity assay in colorectal perfused tumoroid cultures.用于结直肠灌注类器官培养物中药物敏感性测定的重力微流控平台的设计与表征。
Nanomedicine. 2020 Nov;30:102294. doi: 10.1016/j.nano.2020.102294. Epub 2020 Aug 26.
6
Simplified ARCHITECT microfluidic chip through a dual-flip strategy enables stable and versatile tumoroid formation combined with label-free quantitative proteomic analysis.通过双翻转策略简化的 ARCHITECT 微流控芯片可实现稳定且多功能的类器官形成,并结合无标记定量蛋白质组学分析。
Biofabrication. 2021 Apr 8;13(3). doi: 10.1088/1758-5090/abe5b5.
7
Gel-Free 3D Tumoroids with Stem Cell Properties Modeling Drug Resistance to Cisplatin and Imatinib in Metastatic Colorectal Cancer.无胶 3D 类器官具有干细胞特性,可模拟转移性结直肠癌中顺铂和伊马替尼耐药。
Cells. 2021 Feb 6;10(2):344. doi: 10.3390/cells10020344.
8
3D Systems to Model Tumor Angiogenesis and Interactions With Stromal Cells.3D Systems公司将对肿瘤血管生成以及与基质细胞的相互作用进行建模。
Front Cell Dev Biol. 2020 Nov 5;8:594903. doi: 10.3389/fcell.2020.594903. eCollection 2020.
9
Microfluidic-Based 3D Engineered Microvascular Networks and Their Applications in Vascularized Microtumor Models.基于微流控的三维工程微血管网络及其在血管化微肿瘤模型中的应用。
Micromachines (Basel). 2018 Sep 27;9(10):493. doi: 10.3390/mi9100493.
10
Engineering of vascularized 3D cell constructs to model cellular interactions through a vascular network.构建血管化三维细胞结构以通过血管网络模拟细胞间相互作用。
Biomicrofluidics. 2018 May 16;12(4):042204. doi: 10.1063/1.5027183. eCollection 2018 Jul.

引用本文的文献

1
3D cell culture models in research: applications to lung cancer pharmacology.研究中的3D细胞培养模型:在肺癌药理学中的应用
Front Pharmacol. 2024 Sep 23;15:1438067. doi: 10.3389/fphar.2024.1438067. eCollection 2024.
2
Lung cancer organoids: models for preclinical research and precision medicine.肺癌类器官:临床前研究和精准医学的模型
Front Oncol. 2023 Oct 24;13:1293441. doi: 10.3389/fonc.2023.1293441. eCollection 2023.
3
vascularized immunocompetent patient-derived model to test cancer therapies.用于测试癌症治疗方法的血管化免疫活性患者来源模型。

本文引用的文献

1
Generation of Human Lung Organoid Cultures from Healthy and Tumor Tissue to Study Infectious Diseases.从健康组织和肿瘤组织生成人类肺类器官培养物以研究传染病。
J Virol. 2022 Apr 13;96(7):e0009822. doi: 10.1128/jvi.00098-22. Epub 2022 Mar 14.
2
Patient-derived organoids, creating a new window of opportunities for pancreatic cancer patients.患者来源的类器官为胰腺癌患者带来新的机遇之窗。
EMBO Mol Med. 2022 Apr 7;14(4):e15707. doi: 10.15252/emmm.202215707. Epub 2022 Mar 14.
3
Towards organoid culture without Matrigel.朝向无 Matrigel 的类器官培养。
iScience. 2023 Sep 29;26(10):108094. doi: 10.1016/j.isci.2023.108094. eCollection 2023 Oct 20.
4
Patient-Derived Tumoroid for the Prediction of Radiotherapy and Chemotherapy Responses in Non-Small-Cell Lung Cancer.用于预测非小细胞肺癌放疗和化疗反应的患者来源类肿瘤体
Biomedicines. 2023 Jun 26;11(7):1824. doi: 10.3390/biomedicines11071824.
5
Advances in the Lung Cancer Immunotherapy Approaches.肺癌免疫治疗方法的进展
Vaccines (Basel). 2022 Nov 19;10(11):1963. doi: 10.3390/vaccines10111963.
6
Patient-Derived Lung Tumoroids-An Emerging Technology in Drug Development and Precision Medicine.患者来源的肺类肿瘤——药物研发与精准医学中的一项新兴技术。
Biomedicines. 2022 Jul 12;10(7):1677. doi: 10.3390/biomedicines10071677.
Commun Biol. 2021 Dec 10;4(1):1387. doi: 10.1038/s42003-021-02910-8.
4
Establishment of patient-derived cancer organoids for drug-screening applications.建立用于药物筛选应用的患者来源的癌症类器官。
Nat Protoc. 2020 Oct;15(10):3380-3409. doi: 10.1038/s41596-020-0379-4. Epub 2020 Sep 14.
5
The updated landscape of tumor microenvironment and drug repurposing.肿瘤微环境与药物再利用的更新景观。
Signal Transduct Target Ther. 2020 Aug 25;5(1):166. doi: 10.1038/s41392-020-00280-x.
6
3D Bioprinted Vascularized Tumour for Drug Testing.3D 生物打印血管化肿瘤用于药物测试。
Int J Mol Sci. 2020 Apr 23;21(8):2993. doi: 10.3390/ijms21082993.
7
Cancer statistics, 2020.癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
8
Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer.患者来源类器官预测局部晚期直肠癌的放化疗反应。
Cell Stem Cell. 2020 Jan 2;26(1):17-26.e6. doi: 10.1016/j.stem.2019.10.010. Epub 2019 Nov 21.
9
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening.患者来源的肺癌类器官作为体外癌症模型用于治疗筛选。
Nat Commun. 2019 Sep 5;10(1):3991. doi: 10.1038/s41467-019-11867-6.
10
Cancer modeling meets human organoid technology.癌症建模与人类类器官技术相遇。
Science. 2019 Jun 7;364(6444):952-955. doi: 10.1126/science.aaw6985.